Search

Vaxcyte Inc

Avatud

SektorTervishoid

58.03 -1.01

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

56.95

Max

60.14

Põhinäitajad

By Trading Economics

Sissetulek

-284M

-605M

Aktsiakasum

-1.97

Töötajad

507

EBITDA

22M

-292M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+94.24% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

2. nov 2026

Turustatistika

By TradingEconomics

Turukapital

944M

8.7B

Eelmine avamishind

59.04

Eelmine sulgemishind

58.03

Uudiste sentiment

By Acuity

50%

50%

171 / 340 Pingereas Healthcare

Vaxcyte Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. aug 2026, 19:46 UTC

Vaxcyte Inc shares are higher today, supported by broader market gains following positive sentiment from the recent inflation report. The stock remains above its 20-day moving average.

11. aug 2026, 23:11 UTC

Vaxcyte Inc shares are higher in after-market trading, reflecting positive momentum despite no specific news driving the price action.

10. aug 2026, 19:56 UTC

Vaxcyte Inc shares are higher, continuing gains since Friday's close, reaching a peak earlier in the session. No specific news was identified for the move.

7. aug 2026, 21:01 UTC

Vaxcyte Inc shares are lower in after-market hours, continuing a weak trading session without any specific news to explain the decline.

6. aug 2026, 20:03 UTC

News

Vaxcyte reports a net loss of $284.3 million for Q2. Shares are trading higher as the company anticipates key Phase 3 trial data in 2027.

5. aug 2026, 19:16 UTC

Vaxcyte Inc. shares are higher today, aligning with broader market trends, despite no specific news identified. The stock remains near its one-month range low.

4. aug 2026, 20:21 UTC

Vaxcyte Inc. shares are lower in after-market trading, remaining flat since Tuesday's close and positioned below its 20-day moving average.

3. aug 2026, 19:46 UTC

Vaxcyte Inc's shares are lower today, continuing a decline since Friday. The stock is trading near the lower end of its one-month range.

31. juuli 2026, 19:56 UTC

Correlated Moves

Shares lower amid broader sector sentiment; SPDR S&P Biotech ETF declines.

30. juuli 2026, 18:52 UTC

Vaxcyte Inc's shares are higher today amid strong buying activity, reaching an intraday high but remain below the 20-day moving average.

29. juuli 2026, 18:23 UTC

Vaxcyte Inc is lower in Wednesday's session, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

28. juuli 2026, 18:46 UTC

Vaxcyte Inc. shares are trading lower amid broader market trends and volatility, remaining below the 20-day moving average as bond yields decline.

27. juuli 2026, 19:46 UTC

Vaxcyte Inc shares are trading higher today, despite earlier declines and without specific company news. Broader market volatility is influenced by falling crude oil prices.

23. juuli 2026, 19:16 UTC

Vaxcyte Inc shares are lower today amid a broader decline in tech stocks following earnings reports from Alphabet and Tesla. No specific news was identified.

21. juuli 2026, 18:26 UTC

Vaxcyte Inc is trading higher today, continuing its advance since Monday's close. This movement occurs despite concerns over rising treasury yields and geopolitical tensions.

Võrdlus sarnastega

Hinnamuutus

Vaxcyte Inc Prognoos

Hinnasiht

By TipRanks

94.24% tõus

12 kuu keskmine prognoos

Keskmine 114.33 USD  94.24%

Kõrge 163 USD

Madal 75 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Vaxcyte Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

7

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

171 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
help-icon Live chat